Breaking News, Collaborations & Alliances

Sartorius Partners with TheWell Bioscience for Animal-Free Hydrogels & Bioinks

Aims to enable more customers to get more relevant insights in less time, accelerating time to market.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Life science group Sartorius and U.S.-based startup TheWell Bioscience have partnered to further the development of hydrogels and bioinks tailored to produce 3D advanced cell models for drug discovery workflows.
 
Additionally, Sartorius will expand the portfolio of its lab division by distributing TheWell Bioscience’s products and will invest in a minority shareholding in the company.
 
TheWell Bioscience is a pioneer in the field of animal-free hydrogels and bioinks, critical components for the creation of 3D biomimicking platforms, also known as 3D cell models, for precision medicine, cell therapy and biomanufacturing. These models are complex biological structures that mimic the organization and function of cells in living organisms, enabling a more accurate prediction of the efficacy, toxicity, and side effects of drugs in humans. As they address the shift from animal-based to more human-relevant organoid models, 3D cell models are a key strategic growth area for Sartorius.
 
“The offering of TheWell Bioscience seamlessly complements our bioanalytic instruments, cytokines and media products used to grow and analyze a range of 3D spheroid and organoid models. Their hydrogel solutions are highly compatible with our live-cell imaging system for monitoring and analyzing cell health and behavior in real time,” said Fiona Coats, Head of Marketing at Sartorius’ Lab Products & Services division, who will join the board of directors of TheWell Bioscience as part of the collaboration. “By collaborating, we will enable customers to get more relevant insights in less time, accelerating time to market.”
 
“The collaboration with Sartorius will broaden our reach in the life science and biopharma market and enable more customers to speed up their research in advanced biomedicine and personalized therapies,” said John Huang, founder and CEO of TheWell Bioscience.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters